Skip to main content
. 2022 Dec 13;7(17):4765–4772. doi: 10.1182/bloodadvances.2022008937

Figure 3.

Figure 3.

Overall survival stratified by CRS grade. Kaplan-Meier curve showing overall survival for patients who received axicabtagene ciloleucel, showing no significant difference in survival when stratified by CRS grade.